Octreotide Therapy for Managing High Ileostomy Output

Introduction to Octreotide Therapy

The recommended dose of octreotide for managing high ileostomy output is 50 micrograms subcutaneously twice daily 1, 2, 3

Octreotide should be administered subcutaneously, with the standard initial dose being 50 micrograms twice daily 3, 4
The medication should be given before meals as intestinal output, especially in net "secretors," rises after meals 2, 4
Octreotide is most effective in patients with net secretory output (generally more than 3 L/24 hours) and can reduce stomal output by 1-2 L/24 hours 5

Octreotide is a somatostatin analogue that decreases gastric, biliary, and pancreatic secretions 6
It inhibits secretagogue-induced water and electrolyte secretion in the jejunum, stimulates sodium and chloride absorption in the ileum, decreases intestinal motility, and inhibits the release of hormones that may contribute to diarrhea 6
Studies show octreotide can reduce ileostomy diarrhea and large volume jejunostomy output, with the greatest reductions seen in those with net secretory output 1
The effect of octreotide is maintained in the long term 1, 4

Careful monitoring is essential when initiating octreotide therapy to prevent fluid retention, which can occur especially in patients with the highest stomal outputs 7, 6
Objective measurements of the effects should be performed before and during treatment 6
Parenteral support should be reduced accordingly as stomal output decreases 6
Long-term use requires monitoring for potential adverse effects and possible negative interference with the process of intestinal adaptation 7, 6

Restricting oral hypotonic fluids to 500 ml/day can be considered as a first-line intervention before octreotide therapy 5
Using glucose-saline solution with sodium concentration of at least 90 mmol/L can be considered as a first-line intervention before octreotide therapy 4
Administering antimotility drugs such as loperamide (2-8 mg before food) can be considered as a first-line intervention before octreotide therapy 5
Drugs that reduce gastric acid secretion (H2 antagonists or proton pump inhibitors) are as effective as octreotide in reducing stomal output volume and should be considered as alternatives 1, 2
For patients who fail to respond to conventional treatments including octreotide, newer GLP-2 analogues like teduglutide may be considered, though these should only be prescribed by specialists 8

Octreotide should be used especially in the short-term after intestinal resection when fluid and electrolyte management is problematic despite conventional treatments 7
While octreotide reduces stomal output, it does not change the absorption of energy, carbohydrate, lipid, or nitrogen, and may not reduce jejunostomy output enough to eliminate the need for parenteral fluid and electrolyte replacement 1, 2
Long-acting octreotide/somatostatin preparations have not been well assessed in large studies for this indication 1